Acute toxicity of two Alzheimer's disease radiopharmaceuticals: FDDNP and IMPY

Kang Wei Chang, Chia Chieh Chen, Shih Ying Lee, Hsin Ell Wang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that results in memory deficits. The effect of AD is the leading cause of dementia in the United States and constitutes a burgeoning public health problem. AD is characterized by the presence of two aberrant structures, senile plaques, and neurofibrillary tangles, present in the brain of the patients. [18F]FDDNP and [ 123I]IMPY were developed for the early diagnosis of AD by Dr. J. Barrios and Dr. H. Kung, respectively. These two radiotracers could bind with the amyloid location site in the AD patient brain. The aim of this study was to analyze the acute single toxic effects dose of two nonradiochemical labeled compounds in rats. Animals were injected from the tail vein with nonlabeled-FDDNP (05mg/kg) and nonlabeled-IMPY (0-300μg/kg), respectively, and observed for 2 weeks. These doses provide safety margins of 35,000- to 140-fold and 1,000- to 100-fold over the maximal recommend human dose (0.1mg/70kg) and (20μg/60kg) (by FDDNP and IMPY), respectively. With IMPY, there were no changes in mortality, clinical situation, and gross necropsy. With FDDNP, the high dose (5mg/kg) produced mortality in 2 of 5 and 1 of 5 in male and female rats, respectively. The high dose of FDDNP showed liver damage in dying animals. No other adverse toxic effects at dose levels up to 1.0mg/kg of FDDNP were noted. FDDNP exerted no adverse toxic effects in rats given doses up to 1mg/kg and IMPY at the dose levels up to 300 μg/kg.

Original languageEnglish
Pages (from-to)429-437
Number of pages9
JournalDrug and Chemical Toxicology
Volume32
Issue number4
DOIs
Publication statusPublished - Oct 1 2009
Externally publishedYes

Fingerprint

Radiopharmaceuticals
Toxicity
Alzheimer Disease
Poisons
Rats
Brain
Animals
Neurofibrillary Tangles
Mortality
Amyloid Plaques
Memory Disorders
Public health
Medical problems
Amyloid
Neurodegenerative Diseases
Liver
Dementia
Tail
Early Diagnosis
Veins

Keywords

  • Alzheimers disease
  • FDDNP
  • IMPY
  • Toxicity

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Public Health, Environmental and Occupational Health
  • Health, Toxicology and Mutagenesis
  • Chemical Health and Safety

Cite this

Acute toxicity of two Alzheimer's disease radiopharmaceuticals : FDDNP and IMPY. / Chang, Kang Wei; Chen, Chia Chieh; Lee, Shih Ying; Wang, Hsin Ell.

In: Drug and Chemical Toxicology, Vol. 32, No. 4, 01.10.2009, p. 429-437.

Research output: Contribution to journalArticle

Chang, Kang Wei ; Chen, Chia Chieh ; Lee, Shih Ying ; Wang, Hsin Ell. / Acute toxicity of two Alzheimer's disease radiopharmaceuticals : FDDNP and IMPY. In: Drug and Chemical Toxicology. 2009 ; Vol. 32, No. 4. pp. 429-437.
@article{9b6d233baf6e4e449a939c2411ce80f0,
title = "Acute toxicity of two Alzheimer's disease radiopharmaceuticals: FDDNP and IMPY",
abstract = "Alzheimer's disease (AD) is a neurodegenerative disorder that results in memory deficits. The effect of AD is the leading cause of dementia in the United States and constitutes a burgeoning public health problem. AD is characterized by the presence of two aberrant structures, senile plaques, and neurofibrillary tangles, present in the brain of the patients. [18F]FDDNP and [ 123I]IMPY were developed for the early diagnosis of AD by Dr. J. Barrios and Dr. H. Kung, respectively. These two radiotracers could bind with the amyloid location site in the AD patient brain. The aim of this study was to analyze the acute single toxic effects dose of two nonradiochemical labeled compounds in rats. Animals were injected from the tail vein with nonlabeled-FDDNP (05mg/kg) and nonlabeled-IMPY (0-300μg/kg), respectively, and observed for 2 weeks. These doses provide safety margins of 35,000- to 140-fold and 1,000- to 100-fold over the maximal recommend human dose (0.1mg/70kg) and (20μg/60kg) (by FDDNP and IMPY), respectively. With IMPY, there were no changes in mortality, clinical situation, and gross necropsy. With FDDNP, the high dose (5mg/kg) produced mortality in 2 of 5 and 1 of 5 in male and female rats, respectively. The high dose of FDDNP showed liver damage in dying animals. No other adverse toxic effects at dose levels up to 1.0mg/kg of FDDNP were noted. FDDNP exerted no adverse toxic effects in rats given doses up to 1mg/kg and IMPY at the dose levels up to 300 μg/kg.",
keywords = "Alzheimers disease, FDDNP, IMPY, Toxicity",
author = "Chang, {Kang Wei} and Chen, {Chia Chieh} and Lee, {Shih Ying} and Wang, {Hsin Ell}",
year = "2009",
month = "10",
day = "1",
doi = "10.1080/01480540903127324",
language = "English",
volume = "32",
pages = "429--437",
journal = "Drug and Chemical Toxicology",
issn = "0148-0545",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Acute toxicity of two Alzheimer's disease radiopharmaceuticals

T2 - FDDNP and IMPY

AU - Chang, Kang Wei

AU - Chen, Chia Chieh

AU - Lee, Shih Ying

AU - Wang, Hsin Ell

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Alzheimer's disease (AD) is a neurodegenerative disorder that results in memory deficits. The effect of AD is the leading cause of dementia in the United States and constitutes a burgeoning public health problem. AD is characterized by the presence of two aberrant structures, senile plaques, and neurofibrillary tangles, present in the brain of the patients. [18F]FDDNP and [ 123I]IMPY were developed for the early diagnosis of AD by Dr. J. Barrios and Dr. H. Kung, respectively. These two radiotracers could bind with the amyloid location site in the AD patient brain. The aim of this study was to analyze the acute single toxic effects dose of two nonradiochemical labeled compounds in rats. Animals were injected from the tail vein with nonlabeled-FDDNP (05mg/kg) and nonlabeled-IMPY (0-300μg/kg), respectively, and observed for 2 weeks. These doses provide safety margins of 35,000- to 140-fold and 1,000- to 100-fold over the maximal recommend human dose (0.1mg/70kg) and (20μg/60kg) (by FDDNP and IMPY), respectively. With IMPY, there were no changes in mortality, clinical situation, and gross necropsy. With FDDNP, the high dose (5mg/kg) produced mortality in 2 of 5 and 1 of 5 in male and female rats, respectively. The high dose of FDDNP showed liver damage in dying animals. No other adverse toxic effects at dose levels up to 1.0mg/kg of FDDNP were noted. FDDNP exerted no adverse toxic effects in rats given doses up to 1mg/kg and IMPY at the dose levels up to 300 μg/kg.

AB - Alzheimer's disease (AD) is a neurodegenerative disorder that results in memory deficits. The effect of AD is the leading cause of dementia in the United States and constitutes a burgeoning public health problem. AD is characterized by the presence of two aberrant structures, senile plaques, and neurofibrillary tangles, present in the brain of the patients. [18F]FDDNP and [ 123I]IMPY were developed for the early diagnosis of AD by Dr. J. Barrios and Dr. H. Kung, respectively. These two radiotracers could bind with the amyloid location site in the AD patient brain. The aim of this study was to analyze the acute single toxic effects dose of two nonradiochemical labeled compounds in rats. Animals were injected from the tail vein with nonlabeled-FDDNP (05mg/kg) and nonlabeled-IMPY (0-300μg/kg), respectively, and observed for 2 weeks. These doses provide safety margins of 35,000- to 140-fold and 1,000- to 100-fold over the maximal recommend human dose (0.1mg/70kg) and (20μg/60kg) (by FDDNP and IMPY), respectively. With IMPY, there were no changes in mortality, clinical situation, and gross necropsy. With FDDNP, the high dose (5mg/kg) produced mortality in 2 of 5 and 1 of 5 in male and female rats, respectively. The high dose of FDDNP showed liver damage in dying animals. No other adverse toxic effects at dose levels up to 1.0mg/kg of FDDNP were noted. FDDNP exerted no adverse toxic effects in rats given doses up to 1mg/kg and IMPY at the dose levels up to 300 μg/kg.

KW - Alzheimers disease

KW - FDDNP

KW - IMPY

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=74049151575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049151575&partnerID=8YFLogxK

U2 - 10.1080/01480540903127324

DO - 10.1080/01480540903127324

M3 - Article

C2 - 19793037

AN - SCOPUS:74049151575

VL - 32

SP - 429

EP - 437

JO - Drug and Chemical Toxicology

JF - Drug and Chemical Toxicology

SN - 0148-0545

IS - 4

ER -